Evidence map›Paper›PMID 37561800›Full record

ArticlePloS one2023

High risk of virologic failure among HIV-infected children and adolescents routinely followed-up in Littoral region of Cameroon.

Patient Juste Mbébi Enoné, Calixte Ida Penda, Grâce Ngondi, Joseph Fokam, Serge Bruno Ebong, Jerson Mekoulou Ndongo, Estelle Géraldine Essangui Same, Louis Sides Ndjengue Nson, Samuel Honoré Mandengue, Carole Else Eboumbou Moukoko

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Patient Juste Mbébi EnonéFaculty of Sciences, Department of Animal Biology and Physiology, University of Douala, Douala, Cameroon.
Calixte Ida PendaFaculty of Medicine and Pharmaceutical Sciences, Clinical Sciences Department, University of Douala, Douala, Cameroon.
Grâce NgondiFaculty of Medicine and Pharmaceutical Sciences, Biological Sciences Department, University of Douala, Douala, Cameroon.
Joseph FokamChantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaounde, Cameroon.ORCID 0000-0002-1501-2763
Serge Bruno EbongFaculty of Sciences, Department of Animal Biology and Physiology, University of Douala, Douala, Cameroon.
Jerson Mekoulou NdongoFaculty of Sciences, Department of Animal Biology and Physiology, University of Douala, Douala, Cameroon.ORCID 0000-0001-8291-0953
Estelle Géraldine Essangui SameFaculty of Medicine and Pharmaceutical Sciences, Biological Sciences Department, University of Douala, Douala, Cameroon.
Louis Sides Ndjengue NsonAccredited HIV Care Center, Laquintinie Hospital of Douala, Douala, Cameroon.
Samuel Honoré MandengueFaculty of Sciences, Department of Animal Biology and Physiology, University of Douala, Douala, Cameroon.
Carole Else Eboumbou MoukokoFaculty of Medicine and Pharmaceutical Sciences, Biological Sciences Department, University of Douala, Douala, Cameroon.ORCID 0000-0003-3252-6552
University of Douala · CMUniversity of Buea · CM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Virological response to antiretroviral therapy (ART) remains a challenge for HIV-infected children and adolescents due to non-optimization of pediatric ART for resource-limited settings. In this study, we aimed to investigate factors associated with virologic failure (VF) in HIV-infected-children and adolescents on ART in Cameroon. A prospective patient-based cohort study was conducted among HIV-infected children (0-9 years) and adolescents (10-19 years) followed-up between November 2018 and October 2019 in 38 healthcare centers located in the Littoral region of Cameroon. The 1st viral load (VL) was assessed after 6 months of ART initiation and the 2nd VL between 3 and 6 six months later in patients with VL ≥1000 copies/ml in accordance with the national algorithm using Abbott Real-Time HIV-1 Viral Load Assay. Multivariate analyses were performed to identify the determinants of higher risk of VF. Of 1,029 HIV-infected children and adolescents (393 children and 636 adolescents), 801 (77.8%) cumulatively presented with VL <1000 copies/mL within 12 months on ART. Adolescents were more likely to have VF than children (24.5% vs 18.3%, OR: 1.39; 95%CI: 1.00-1.93; p = 0.047). Patients followed-up in decentralized care units were significantly more likely to have VF compared to those attending the accredited treatment centers (26.1% vs 16.6%, OR: 1.88, 95%CI: 1.37-2.58; p<0.001). Our findings show a high rate of VL suppression (VLS, 77.8%) among HIV-infected children and adolescents, albeit lower than the established target of 90%. Being adolescent and patients followed in the decentralized care units are high risk factors for VF, thereby necessitating routine therapeutic education of patients and guardians in resource limited countries to improve VLS.

Indexed as

Anti-HIV AgentsHIV InfectionsAdolescentAntiretroviral Therapy, Highly ActiveCameroonChildCohort StudiesHumansProspective StudiesTreatment FailureViral LoadAnti-HIV Agents

Identifiers

PMID37561800
PMCPMC10414642
OpenAlexW4385727319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.